PTC Therapeutics may repurchase up to $500 million of its stock
PTC Therapeutics' board approved a share buyback of up to $500 million, according to Dow Jones Newswires. The stock rose 11% in midday trading on Tuesday.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The board of PTC Therapeutics has approved a plan to buy back its own shares worth up to $500 million, Dow Jones Newswires reports. The Warren, New Jersey-based biopharmaceutical company said on Tuesday that the move reflects its confidence in the business and in its growth prospects over both the near and long term.
Chief Executive Officer Matthew Klein said the company sees its shares as a compelling opportunity while keeping enough financial room to support current programs and pursue possible business development deals.
During Tuesday's midday session the shares climbed 11% to $67.44, though they remain down 11% so far this year. The company has a market value of about $5.08 billion and roughly 80.9 million shares available for trading.
why it matters
The news concerns a single company, but the size of the program is notable against a market capitalization of about $5.08 billion. Buybacks like this often support the share price and signal that management views the stock as undervalued, though the effect on the broader biotech sector is likely limited.
tags
instruments
sources
- PTC Therapeutics May Buy Back $500M of Stock to Take Advantage of `Compelling Opportunity' — Dow Jones Newswires, 3 November 2026 at 19:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗